| Literature DB >> 19840690 |
Gerald J Kost1, Kristin N Hale, T Keith Brock, Richard F Louie, Nicole L Gentile, Tyler K Kitano, Nam K Tran.
Abstract
Objective evidence-based national surveys serve as a first step in identifying suitable point-of-care device designs, effective test clusters, and environmental operating conditions. Preliminary survey results show the need for point-of-care testing (POCT) devices using test clusters that specifically detect pathogens found in disaster scenarios. Hurricane Katrina, the tsunami in southeast Asia, and the current influenza pandemic (H1N1, "swine flu") vividly illustrate lack of national and global preparedness. Gap analysis of current POCT devices versus survey results reveals how POCT needs can be fulfilled. Future thinking will help avoid the worst consequences of disasters on the horizon, such as extensively drug-resistant tuberculosis and pandemic influenzas. A global effort must be made to improve POC technologies to rapidly diagnose and treat patients to improve triaging, on-site decision making, and, ultimately, economic and medical outcomes.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19840690 PMCID: PMC7115727 DOI: 10.1016/j.cll.2009.07.014
Source DB: PubMed Journal: Clin Lab Med ISSN: 0272-2712 Impact factor: 1.935
SurveyMonkey Instructions
| Step | Instruction and Access |
|---|---|
| One | Visit UC Davis-LLNL POCT. |
| Web site: | |
| Two | The Clinical Needs Assessment survey link appears in the top right corner of the navigation bar. It is the first item under POC Technologies Center. Please click on “Needs Assessment Survey” |
| Three | Please contact Keith Brock, Research Specialist, at 530 752 8471, email: |
| Four | Follow the instructions on the screen to complete the survey. |
| Five | Thank you for your time and input on the survey! |
Fig. 1Device design format. Visual logistics were used to illustrate 3 device format selections for POCT instruments. (A) Transportable device on a cart. (B) Portable, bench-top device with a handle for carrying. (C) Small battery-operated handheld device.
Fig. 2Selection of format by survey respondents. In disaster settings, participants preferred handheld devices (∗∗∗P<.001). For urgent care and emergency-room settings, there were no statistically significant differences in preferences.
Fig. 3Multiple patients versus multiplex pathogens. Visual logistics were used to illustrate 2 testing methods for POCT devices. (A) Testing multiple patients for 1 pathogen. (B) Multiplex pathogen testing, in which 1 patient sample is simultaneously tested for the presence of multiple pathogens (underline).
Fig. 4Selection of testing method by survey respondents. In disaster settings, both approaches to pathogen detection may be useful. However, respondents preferred multiplex testing to testing multiple patients for 1 pathogen in urgent care (∗∗∗P<.001) and emergency room (∗∗P<.01) settings.
Fig. 5Test cassettes versus vacutainers. Visual logistics were used to illustrate 2 sample collection methods for POCT instruments. (A) A vacutainer is used to collect the blood sample, allowing for multiple blood collection tubes to be drawn at one time. (B) Test cassette blood sample collection; blood is drawn directly into a disposable test cassette, processed, and a result given. Graphics updated for the survey currently in use.
Fig. 6Selection of sample collection method by survey respondents. Test cassettes and vacutainers were equivalent in all but the disaster setting, but this result was not statistically significant in this preliminary survey report.
Fig. 7Biohazard disposal methods. Visual logistics were used to illustrate 2 biohazard disposal methods for POCT devices. (A) Biohazard waste in a reusable waste storage reservoir that must be emptied periodically, and a disposable test cassette for single use. (B) A device that stores all biohazard waste in a disposable test cassette that is discarded after a single use. Graphics updated for the survey currently in use.
Fig. 8Uniform selection of waste disposal by disposable test cassette by survey respondents. There is a statistically significant preference for disposable test cassettes across all 3 clinical settings (P<.01, 0.05, and 0.01). See Fig. 6. Disposable test cassettes have merit for sample collection and waste disposal in disaster settings. ∗P<.05; ∗∗P<.01.
Pathogen test clusters
| Weighted Score | Pathogen | |
|---|---|---|
| A. General disaster test cluster (n = 18) | 117 | |
| 108 | ||
| 100 | ||
| 77 | Yellow fever | |
| 73 | ||
| 66 | ||
| 62 | ||
| 54 | ||
| 49 | Dengue fever virus | |
| 38 | ||
| B. Blood donor screening test cluster (n = 23) | 224 | HIV 1 and 2 |
| 190 | Hepatitis B | |
| 190 | Hepatitis C | |
| 125.5 | Human T cell lymphotropic virus 1 and 2 (HTLV 1 and 2) | |
| 109.5 | West Nile virus | |
| 109 | ||
| 93 | Dengue fever | |
| 77 | Parvovirus B19 | |
| 74 | Epstein-Barr virus | |
| 46 | Chikungunya | |
| C. Bloodstream pathogen test cluster (n = 20) | 147 | Methicillin-resistant |
| 118 | ||
| 91 | ||
| 90.5 | ||
| 90 | ||
| 87.5 | Methicillin-sensitive | |
| 79 | ||
| 61 | ||
| 50 | ||
| 48 | Coagulase-negative | |
| D. Pandemic test cluster (n = 22) | 189 | |
| 121.5 | ||
| 115.5 | ||
| 112.5 | Respiratory syncytial virus | |
| 112.5 | Methicillin-resistant | |
| 100 | ||
| 90.5 | ||
| 87 | Adenovirus | |
| 57 | ||
| 51.5 | Metapneumovirus |
Pathogens in disasters
| Scenario | Location, Year | Pathogens Detected (Isolation Site) | Path of Infection |
|---|---|---|---|
| Drought | Florida, 5 epidemics since 1952 | Saint Louis encephalitis (blood) | Vector borne |
| West Nile (blood) | Vector borne | ||
| Indonesia, 1997 | Malaria (blood) | Vector borne | |
| Earthquake | California, 1994 | Dust cloud | |
| China, 2008 | Wound | ||
| Wound | |||
| Wound | |||
| Wound | |||
| Wound | |||
| Turkey, 1999 | Wound | ||
| Wound | |||
| Methicillin-resistant | |||
| Wound | |||
| Wound | |||
| Turkey, 1999 | Wound | ||
| Wound | |||
| Methicillin-resistant | |||
| Wound | |||
| Wound | |||
| Wound | |||
| Wound | |||
| Wound | |||
| Flooding | Bangladesh, 2004 | Water, food borne | |
| Global, 1980–2008 | Malaria (blood) | Vector borne | |
| Yellow fever (blood) | Vector borne | ||
| West Nile (blood) | Vector borne | ||
| Dengue (blood) | Vector borne | ||
| Indonesia, 2004 | Water, food borne | ||
| Nonspecific | Inhalation | ||
| Hurricanes/tornadoes | Katrina, 2005 | Nontoxigenic | Food borne |
| Water borne | |||
| Wound, food borne | |||
| Wound, food borne | |||
| Methicillin-resistant | Wound | ||
| Norovirus (stool) | Water borne | ||
| Water borne | |||
| Water borne | |||
| Water borne | |||
| Water borne | |||
| Water borne | |||
| Water borne | |||
| Georgia, 2000 | Wound | ||
| Wound | |||
| Enterococcus (wound) | Wound | ||
| Low-resource settings/rural areas | Indonesia, 2001–2003 | Food, water borne | |
| Food, water borne | |||
| Food, water borne | |||
| Philippines, 1994–1996 | Inhalation | ||
| Inhalation | |||
| Tsunamis | Thailand, 2004 | Wound | |
| Water, food borne | |||
| Wound | |||
| Wound | |||
| Soil, water borne | |||
| Soil, water borne | |||
| Soil, water borne | |||
| Methicillin-resistant | |||
| Wound | |||
| Wound | |||
| Inhalation, wound | |||
| Inhalation, wound | |||
| Inhalation, wound | |||
| Water borne | |||
| Soil | |||
| Water borne | |||
| World Trade Center disaster | New York, 2001 | Asthma and WTC cough (pathogens not named) |
Fig. 9Locations and types of POCT in Hurricane Katrina. Hospitals, evacuation sites, and local agencies were not prepared fully to assist quickly with POCT. They carried few POCT instruments. In contrast, US military ships and combat support units were equipped with POCT devices, including a variety of tests to facilitate rapid diagnosis and treatment. Donations of glucose meters proved valuable, but not fast enough or adequate for the large numbers of diabetic victims involved in the disaster. POC tests used during the disaster include: ALP, alkaline phosphatase; ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; BUN, blood (serum) urea nitrogen; CK, creatine kinase; cTn, cardiac troponin; GGT, γ-glutamyltransferase; Hb, hemoglobin; Hct, hematocrit; HDL, high-density lipoprotein; INR, international normalized ratio; LD, lactate dehydrogenase; MB, MB fraction of CK; PT, prothrombin time; SO2, oxygen saturation measured by pulse oximetry; TCO2, total carbon dioxide content; TP, total protein. Instrument identifications: Bayer Acsensia, http://www.bayercarediabetes.com; Cardiac STATus, http://www.spectraldx.com; Cell-Dyn, http://www.abbottdiagnostics.com; i-STAT, http://www.i-stat.com; Ortho Diagnostics blood typing, http://www.orthoclinical.com; Piccolo, http://www.abaxis.com; Rapidpoint coag, http://www.bayer-poct.co.uk; and Triage, http://www.biosite.com. (From Kost GJ, Tran NK, Tuntideelert M, et al. Hurricane Katrina, the tsunami and point-of-care testing: optimizing rapid response diagnosis in disasters. Am J Clin Pathol 2006;126:513–20. © 2006 American Society for Clinical Pathology; Courtesy of Knowledge Optimization, Davis, CA; with permission.)
Fig. 10Hurricane Katrina disaster areas, arrival times of military and civilian assets, sequential responses, and optimal POCT plan for disaster response. Mobile and military resources, including POCT, arrived on days 1, 3 to 5, 9, and 24. At the community and regional hospitals surveyed, beds averaged 154 (SD, 66; median, 173; range, 60–211) and 397 (SD, 249; median, 326; range, 174–763), respectively. Physicians ranged from 50 to 900. Displacement of 5944 physicians from the disaster area (223,000 km2) hampered an already devastated health care infrastructure. The authors recommend (upper right) optimizing disaster response by prepositioning POCT for emergency use during the first 2 critical days. ICU, intensive care unit; OR, operating room. (From Kost GJ, Tran NK, Tuntideelert M, et al. Hurricane Katrina, the tsunami and point-of-care testing: optimizing rapid response diagnosis in disasters. Am J Clin Pathol 2006;126:513–20. © 2006 American Society for Clinical Pathology; Courtesy of Knowledge Optimization, Davis, CA; with permission.)
POC influenza diagnostic tests
| Instrument/Manufacturer | Performance Characteristics (%) | ||||||
|---|---|---|---|---|---|---|---|
| Immunoassay Tests | Type | Target | Time | Sensitivity | Specificity | PPV | NPV |
| 3M Rapid Detection Flu A+B | Chromatographic immunoassay | Influenza A | 15 min | 70 | 100 | 99 | 93 |
| Influenza B (nucleoprotein) | 87 | 99 | 88 | 98 | |||
| BD Directigen EZ Flu A+B, | Chromatographic immunoassay | Influenza A | 15 min | 77–91 | 86–99 | 60–98 | 93–95 |
| Influenza B | 69–100 | 99–100 | 93–98 | 93–100 | |||
| BD Directigen Flu A Kit | Immunoassay | Influenza A (nucleoprotein) | 15 min | 67–96 | 88–97 | NA | NA |
| BD Directigen Flu A + BKit | Immunoassay | Influenza A | 15 min | 77–96 | 90–91 | 63–71 | 94–99 |
| Influenza B (nucleoprotein) | 71–88 | 98–100 | 82–100 | 98–100 | |||
| BinaxNOW Influenza A&B | Chromatographic immunoassay | Influenza A | 15 min | 77–83 | 96–99 | 88–97 | 95–96 |
| Influenza B (nucleoprotein) | 50–69 | 100 | 82–100 | 99 | |||
| ESPLINE Influenza A&B, | Chromatographic immunoassay | Influenza A | 15 min | 67 | 100 | 100 | 89 |
| Influenza B (nucleoprotein) | 30 | 100 | 100 | 96 | |||
| fluID Rapid Influenza Test, | Lateral flow immunoassay | Influenza A | NA | NA | NA | NA | NA |
| Influenza B | NA | NA | NA | NA | NA | ||
| Subtype A/H1 | NA | NA | NA | NA | NA | ||
| Subtype A/H3 | NA | NA | NA | NA | NA | ||
| Influ-A&B Respi-Strip, | Chromatographic immunoassay | Influenza A | 15 min | 97 | 100 | 100 | 98 |
| Influenza B (nucleoprotein) | 97 | 100 | 100 | 98 | |||
| OSOM Influenza A & B Test, | Chromatographic immunoassay | Influenza A | 10 min | 74 | 96 | 90 | 90 |
| Influenza B (nucleoprotein) | 60 | 96 | 73 | 94 | |||
| panfluID Rapid Influenza Test, | Lateral flow immunoassay | Avian Influenza | NA | NA | NA | NA | NA |
| QuickVue Influenza A+B Test, | Lateral flow immunoassay | Influenza A | 10 min | 77–94 | 89–99 | 62–91 | 95–99 |
| Influenza B (nucleoprotein) | 62–82 | 97–99 | 80–90 | 94–97 | |||
| QuickVue Influenza Test, | Lateral flow immunoassay | Influenza A+B | 10 min | 73–81 | 96–99 | 92–96 | 85–93 |
| No differentiation (nucleoprotein) | |||||||
| Rockeby Influenza A Test, | Immunoassay | Influenza A (nucleoprotein) | 10 min | 10 | 100 | 100 | 74 |
| SAS FluAlert, | Chromatographic immunoassay | Influenza A | 15 min | 76 | 98 | 93 | 91 |
| Influenza B (nucleoprotein) | 15 min | 91 | 99–100 | 100 | 99 | ||
| Xpect Flu A&B Test Kit, | Chromatographic immunoassay | Influenza A | 15 min | 90–100 | 100 | 100 | 97–100 |
| Influenza B (nucleoprotein) | 83–100 | 100 | 100 | 99–100 | |||
| Primer design, | Real time qPCR | H1N1 (swine flu) | <2 h | NA | NA | NA | NA |
| proFLU plus, | Real time RT-PCR | Influenza A (matrix) | 3 h | 100 | 93 | 71 | 100 |
| Influenza B (nonstructural NS1 & NS2) | 98 | 99 | 80 | 100 | |||
Data shown in the table are from product inserts unless otherwise noted.
Abbreviations: BD, Becton-Dickinson; NA, not available; NPV, negative predictive value; PPV, positive predictive value; qPCR, quantitative polymerase chain reaction; RSV, respiratory syncytial virus; RT, reverse transcriptase; SARS, severe acute respiratory syndrome.
FDA-approved.
CE-approved.
CLIA-waived.
In development.